GlassScriptPhysician profile
Robin L Rochow
NPI 1356590186
$4,629.89
in general payments reported to CMS, 2019-2025
27 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $625 · 2023: $2,135 · 2024: $1,146 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,672 · Consulting Fee: $875 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,671.81 |
| Consulting Fee | $875.00 |
| Education | $154.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,057.08 | 2022-2024 | Xolair |
| Astrazeneca Pharmaceuticals LP | $888.75 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Grifols USA, LLC | $428.62 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Alexion Pharmaceuticals, INC. | $382.49 | 2021-2025 | |
| Glaxosmithkline, LLC. | $377.31 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $209.11 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $154.90 | 2023-2024 | |
| Mylan Specialty L.P. | $143.23 | 2022-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $103.12 | 2024-2025 | |
| Insightec,INC | $101.35 | 2024 | Exablate |
| Neurelis, INC. | $98.25 | 2022 | |
| Optinose US, INC. | $85.04 | 2021-2024 | |
| Inspire Medical Systems, INC. | $67.93 | 2024 | Inspire |
| Amgen INC. | $67.36 | 2023 | Tezspire |
| Csl Behring | $60.99 | 2023-2025 | Hizentra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $54.18 | 2023 | Symtuza |
| Boston Scientific Corporation | $53.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.19 | 2021 | |
| Viatris Specialty LLC | $43.44 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $38.81 | 2021-2025 | Eohilia |
| Biocryst US Sales Co., LLC | $30.22 | 2024 | Orladeyo |
| Alk-Abello, INC | $29.85 | 2021-2023 | Ragwitek, Grastek, Odactra |
| Kyowa Kirin, INC. | $29.55 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $24.07 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $21.43 | 2021 | |
| Kaleo, INC. | $19.57 | 2021 | |
| Eyevance Pharmaceuticals LLC | $16.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Rochow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.